GDF-8 (Myostatin) — EU research guide.

What is GDF-8 (Myostatin)?

GDF-8 (myostatin) is a protein of the TGF-beta family that is made mainly in skeletal muscle and was identified in 1997 as a negative regulator of muscle growth. The human precursor has 375 amino acids; the active form is a disulfide-linked homodimer of the mature chain (about 25 kDa). Mature myostatin is held in a latent complex with its propeptide until tolloid-like metalloproteinases activate it, and it is regulated by binding proteins such as follistatin-related proteins. The vials sold on the research market are presumably recombinant mature myostatin made in cell culture rather than chemically synthesised, but the exact product and source used by any given EU vendor could not be verified.

What does the research show?

In mice, deleting the gene gave animals with muscles weighing 2-3 times more than normal (McPherron 1997), and a child with a myostatin gene mutation and marked muscle hypertrophy was reported in 2004 (Schuelke et al.). No published human trial giving recombinant myostatin to people was found, and because the protein limits muscle growth, the research literature gives no rationale for one. Human trials exist for drugs that block myostatin or related signalling: lean mass rose by about 3-8% across trials, far below the 25-50% seen in mice, and functional benefit was inconsistent (Lee et al. 2023). The phase 2 domagrozumab trial in 120 boys with Duchenne muscular dystrophy did not meet its primary endpoint (4-stair-climb time at week 49) and was stopped early, although MRI showed changes in muscle volume (Sherlock 2022). The bimagrumab phase 3 trial in inclusion body myositis was terminated early for lack of efficacy, and a second sarcopenia trial failed to repeat the first (Lee 2023). The antibody apitegromab is reported by its sponsor to have succeeded in a phase 3 spinal muscular atrophy trial; it is not yet approved.

EU legal status

Recombinant myostatin protein is not an authorised medicine in the EU, and commercial recombinant GDF-8 is labelled for research use only (for example R&D Systems 788-G8). No myostatin-blocking drug is authorised in the EU either: apitegromab (Scholar Rock) has a marketing authorisation application under EMA review, with the CHMP opinion reported as delayed by manufacturing-site inspection issues (BioPharm International, 20 July 2026). In the US, the FDA action date for apitegromab was 30 September 2026, and it was not approved as of the sponsor's 7 August 2026 release. WADA prohibits myostatin inhibitors, including myostatin-binding proteins (S4.3), but this wording was read from a mirror copy of the 2026 list and its example list was slightly garbled; the status of the protein itself is therefore 'not named', not 'permitted', and the S0 class for non-approved substances may also apply.